Anti-L1CAM Antibody Program
Aggressive malignancies (unspecified cancer types)
Pre-clinicalActive
Key Facts
Indication
Aggressive malignancies (unspecified cancer types)
Phase
Pre-clinical
Status
Active
Company
About Elthera
Elthera AG is a private, Zurich-based biotech focused on oncology, specifically targeting L1CAM, an adhesion molecule linked to aggressive tumors and poor prognosis. The company is in the pre-clinical/early development stage, leveraging a management team with deep experience from ESBATech/Novartis and a proven track record in biologics development, including the successful development of Brolucizumab. Its strategy involves a personalized healthcare approach, combining proprietary antibodies with diagnostics to treat patients with the most severe malignancies. A key recent milestone was the 2023 licensing agreement with LegoChem Biosciences for a first-in-class antibody.
View full company profile